Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

643 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C, North S, Donskov F, Rini BI, Choueiri TK. Heng DY, et al. Among authors: tan mh. Ann Oncol. 2012 Jun;23(6):1549-55. doi: 10.1093/annonc/mdr533. Epub 2011 Nov 5. Ann Oncol. 2012. PMID: 22056973 Free PMC article.
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.
Wang Y, Choueiri TK, Lee JL, Tan MH, Rha SY, North SA, Kollmannsberger CK, McDermott DF, Heng DY. Wang Y, et al. Among authors: tan mh. Br J Cancer. 2014 Mar 18;110(6):1433-7. doi: 10.1038/bjc.2014.28. Epub 2014 Feb 18. Br J Cancer. 2014. PMID: 24548864 Free PMC article.
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA. Heng DY, et al. Among authors: tan mh. Ann Oncol. 2014 Jan;25(1):149-54. doi: 10.1093/annonc/mdt492. Ann Oncol. 2014. PMID: 24356626 Free PMC article.
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.
Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY. Ko JJ, et al. Among authors: tan mh. Br J Cancer. 2014 Apr 15;110(8):1917-22. doi: 10.1038/bjc.2014.25. Epub 2014 Apr 1. Br J Cancer. 2014. PMID: 24691425 Free PMC article.
Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial.
Chew CK, Wang R, Bavanandan S, Zainudin N, Zhao X, Ahmed S, Nair D, Hou L, Yahya R, Ch'ng SS, Pang LH, Abdul Aziz A, Huang H, Rajasuriar R, Wu S, Zhang Z, Wang X, Chun GY, Mohd Norzi A, Cheah KY, Lee YL, Wan Mohamad WH, Mohd Din MR, Wan Ahmad Kamil WMR, Tan MH, Xu X, Wang L, Yan M, Liu Y, Chin VK, Teo JS, Lim TO, Zhu T, Gou J, Ng SSM. Chew CK, et al. Among authors: tan mh. NPJ Vaccines. 2024 Oct 31;9(1):209. doi: 10.1038/s41541-024-01003-x. NPJ Vaccines. 2024. PMID: 39482336 Free PMC article.
643 results